M&A / Deals GSK bolts on siRNA drug from China’s SiranBio in $1bn deal PharmaphorumGSK has extended its pipeline of siRNA drugs once again by licensing an ALK7-targeted therapy for cardiometabolic diseases from SiranBio.Read full story pharminent May 6, 2026 (Last updated: May 6, 2026) Pharmaphorum GSK has extended its pipeline of siRNA drugs once again by licensing an ALK7-targeted therapy for cardiometabolic diseases from SiranBio. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: CellCentric raises $220M for a ‘transformative’ multiple myeloma medicineNext: CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026 Related Stories M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy pharminent June 22, 2026 M&A / Deals Lilly bets up to $800M for BioArctic’s brain delivery tech pharminent June 22, 2026 M&A / Deals Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance pharminent June 22, 2026
